UNION is a clinical-stage, pharmaceutical development company focused on identifying, developing and commercializing treatments for immunology. Our current portfolio is comprised of medicinal compounds with established modes of action that hold significant potential to address unmet medical needs. UNION is based in Greater Copenhagen, Denmark, and is led by an international team of biotech entrepreneurs and seasoned pharma executives.

Our strategic focus

UNION works with a scalable and capital-efficient business model built on identification and development of well-characterized molecules with broadly applicable modes of action and demonstrated safety within immunology. The ambition is to maintain a clinical-stage pipeline with shorter time to market while yielding multiple growth opportunities through expansion of scope for existing molecules, through the introduction of new molecules from existing platforms, as well as through in-licensing of new molecules.

Addressing unmet medical needs

UNION is developing orismilast, a high potency next-generation PDE4 inhibitor with demonstrated broad anti-inflammatory properties selected based on an attractive therapeutic window (i.e., the combination of improved efficacy and tolerability). Orismilast holds the potential to be a first-in-class and best-in-class treatment within immunology, one of the largest and fastest growing therapeutic areas where unmet medical needs exist